Quantum BioPharma Ltd. (QNTM) generates news across clinical development, capital markets, licensing, and legal proceedings, reflecting its role as a biopharmaceutical company focused on neurodegenerative and metabolic disorders and alcohol misuse disorders. Many of its recent announcements center on Lucid-21-302 (Lucid-MS), a patented new chemical entity developed through its subsidiary Lucid Psycheceuticals Inc. News items describe progress in toxicity and toxicokinetic studies, Phase 1 clinical work, and preparations for an Investigational New Drug (IND) application with the U.S. FDA, as well as a joint PET imaging study with Massachusetts General Hospital scientists to monitor myelin integrity in multiple sclerosis.
Investors following QNTM news will also see updates on financial results, balance sheet developments, and capital structure changes, including private placements, warrant expirations, at-the-market offering agreements, and the issuance of contingent value rights (CVRs) linked to potential recoveries from litigation. The company’s disclosures highlight its digital asset portfolio, comprised mainly of Bitcoin and other cryptocurrencies, and provide commentary on realized gains and treasury management.
Another recurring theme in Quantum BioPharma’s news flow is its relationship with Unbuzzd Wellness Inc., licensee of the unbuzzd asset. Press releases cover Unbuzzd Wellness Inc.’s capital raising plans, investor webinars, and positioning of unbuzzd as a beverage or supplement aimed at alcohol metabolism and related symptoms, while noting Quantum BioPharma’s equity stake and royalty rights.
In addition, Quantum BioPharma issues updates on its lawsuit alleging stock market manipulation and stock spoofing involving major financial institutions, including coverage by investigative news program W5. These items outline the company’s allegations, the scale of the claimed damages, and the link between the litigation and the CVR structure. For readers and investors, the QNTM news stream offers a consolidated view of clinical milestones, financial reporting, licensing activity, and legal developments related to Quantum BioPharma.
Quantum BioPharma (QNTM) reported third-quarter 2026 results, with shareholders’ equity rising approximately 91% since December 2025 to US$9.77 million. Cash and digital assets totaled approximately US$12.22 million at September 30, versus US$4.12 million at December 31, excluding US$1.60 million then restricted. Management considers these holdings sufficient for planned operations over the next twelve months.
Nine-month operating expenses fell approximately 32% to US$8.81 million; net loss narrowed to US$17.32 million from US$23.25 million. Following FDA clearance in August, Quantum signed an October 6 Study Start-Up Agreement with Thermo Fisher Scientific’s clinical research business for its Lucid-MS Phase 2 trial in progressive multiple sclerosis. In October, Quantum extended its loan to Unbuzzd to December 31, 2027, and subscribed for 1,500,000 shares at C$0.20 each, holding 19.87% after the placement.
Quantum BioPharma (NASDAQ: QNTM) closed a private placement of 26 Class A multiple voting shares on November 9, 2026.
Xorax Family Trust and Fortius Research and Trading each bought 13 shares at C$3.11 per share, generating C$80.86 in gross proceeds. Class A voting power rose from approximately 57.01% to 68.22%; each share carries 276,660 votes. The placement used prior authorization and was not conditional on the new shareholder resolution.
At the November 10 meeting, disinterested Class B holders approved continuing authority to issue Class A shares to permitted holders to maintain up to 70% voting power. Shareholders also authorized a consolidation of up to 10 pre-consolidation shares for one post-consolidation share and a discretionary name change. They elected all five director nominees, reappointed the auditor and approved the 2026 omnibus equity incentive plan.
Quantum BioPharma (NASDAQ: QNTM) filed a supplement correcting fractional-share treatment under its proposed share consolidation and clarifying a voting-power cap. The supplement revises the consolidation resolution for Class A multiple voting shares and Class B subordinate voting shares at the November 10, 2026 shareholder meeting, scheduled for 1:00 p.m. Eastern time.
Fractions equal to or below one-half share will round down; fractions above one-half will round up. If Class B share cancellations would push multiple voting shareholders above 70% of aggregate voting power, the company will implement a measure capping their voting power at 70%. Previously submitted proxies remain valid unless properly revoked or changed. No amended proxy form will be distributed.
Quantum BioPharma (QNTM) signed a Study Start-Up Agreement with Thermo Fisher Scientific’s clinical research business to implement its Phase 2 Lucid-MS trial. The agreement initiates formal study start-up activities following FDA clearance to proceed with the planned trial. Thermo Fisher’s PPD Clinical Research Business will support start-up work and related clinical research services.
The planned randomized, double-blind, placebo-controlled study will evaluate Lucid-MS efficacy, safety and tolerability in people with progressive forms of multiple sclerosis. This design compares treatment with placebo while keeping treatment assignments concealed from participants and researchers. Clinical assessments and imaging measures will examine disease progression and biology. The contract marks study preparation, rather than a report of Phase 2 treatment results.
Quantum BioPharma (QNTM) announced on September 24, 2026, that its licensee Unbuzzd Wellness appointed Michael Zapolin as CEO.
Zapolin is tasked with financing and listing Unbuzzd on a stock exchange, followed by a nationwide U.S. marketing and product rollout. Former CEO Richard Buzbuzian is assisting with the transition. Unbuzzd expects its transition to a public listing to become effective next quarter.
Quantum held 19.48% of Unbuzzd as of June 30, 2026. Its agreement provides a 7% royalty on unbuzzd sales until payments to Quantum reach $250 million, then 3% in perpetuity. In a completed placebo-controlled trial, the rate of blood alcohol concentration reduction was, on average for most participants, more than 40% faster within 30 minutes than for controls. Headache severity was 67% lower at four hours versus placebo.
Quantum BioPharma (QNTM) announced that Rodman & Renshaw has initiated analyst coverage with a BUY rating and a US$8 price target.
The initiation research report is led by Michael G. King Jr., Director of Research and Senior Biotechnology Analyst at Rodman & Renshaw. The company states that the coverage is unpaid, with Quantum BioPharma providing no consideration or fees for the report. A copy of the initiation report is available through the referenced “Quantum Published Initiation Report.”
Quantum BioPharma (QNTM) will present at the 3rd Annual ArcStone-Kingswood Growth Summit in Toronto on September 16, 2026.
The company will discuss recent milestones, including U.S. FDA approval of its Investigational New Drug application for Lucid-MS, enabling initiation of Phase 2 trials in patients with progressive multiple sclerosis, an area the company describes as a substantial unmet medical need. Lucid-MS is a patented new chemical entity investigational candidate designed to provide neuroprotection by inhibiting demyelination and targeting underlying neurodegeneration.
Quantum also highlights its economics from UNBUZZD™, retaining a 19.48% ownership stake in Unbuzzd Wellness as of June 30, 2026 and a royalty stream of 7% of unbuzzd™ sales until cumulative payments reach $250 million, after which the royalty declines to 3% in perpetuity, while keeping 100% of rights for pharmaceutical and medical formulations.
Quantum BioPharma (QNTM) received FDA clearance to begin a phase 2 clinical trial of Lucid-MS in patients with multiple sclerosis. The candidate is described as a patented, first-in-class therapy designed to protect and potentially rebuild the myelin sheath, targeting the underlying mechanism of MS rather than immune suppression. This would be the first human MS trial for a drug using this specific mechanism, and the milestone has already attracted a new buy rating from Wall Street analysts, according to the company. Quantum’s Lucid-MS program is advanced through wholly owned subsidiary Lucid Psycheceuticals.
Quantum also highlights its economic interest in UNBUZZD(TM), holding 19.84% of Unbuzzd Wellness and entitled to a 7% royalty on unbuzzd(TM) sales until cumulative payments reach $250 million, after which royalties decline to 3% in perpetuity.
Quantum BioPharma (QNTM) has received FDA clearance to begin a phase 2 clinical trial of Lucid-MS, a patented, first-in-class multiple sclerosis drug candidate focused on protecting and potentially repairing the myelin sheath rather than modulating the immune system.
The company states this will be the first time a drug using this specific mechanism is tested in people living with MS, and notes that the milestone has already attracted a new buy rating from Wall Street analysts. Lucid-MS, developed via subsidiary Lucid Psycheceuticals, has shown prevention and reversal of myelin degradation in preclinical models. Quantum also highlights economic interests in UNBUZZD(TM), retaining 19.84% ownership in Unbuzzd Wellness and a royalty on unbuzzd(TM) sales, starting at 7% until cumulative payments reach $250 million, then 3% in perpetuity.
Quantum BioPharma (NASDAQ/CSE: QNTM) reported Q2 2026 results showing stronger liquidity and a key regulatory advance for its lead MS program. As of June 30, 2026, combined cash, cash equivalents and digital assets were approximately US$9.5 million, up from US$4.1 million at December 31, 2025, with cash alone rising to US$3.65 million. Total shareholders’ equity increased about 19% to US$6.09 million, and working capital improved to roughly US$1.66 million. Management expects this liquidity to fund planned operations at least to October 2027, assuming a cash burn rate similar to the first half of 2026.
Operating expenses fell 53% year-over-year in Q2 to US$2.29 million, with G&A down 47%, and cash used in operating activities for the first half down 44% to US$3.46 million. According to Quantum, the FDA has approved its IND for Lucid-MS, enabling a randomized, double-blind, placebo-controlled Phase 2 trial in progressive multiple sclerosis. Quantum also highlights its 19.48% stake and tiered royalty agreement with Unbuzzd Wellness for UNBUZZD™.